Li Yan, M.D., Ph.D., is Chief Medical Officer and has overall responsibility for clinical development, regulatory affairs, medical affairs, drug safety, and other related functions. He is accountable for developing and driving execution of clinical development programs and registrations in China.


Prior to joining the company, Dr. Yan was Vice President and Head Unit Physician of GSK Oncology, where he oversaw global development of oncology assets focusing on immunotherapy, cancer epigenetics, and cell therapy. Prior to his tenure at GSK, he was Executive Director at Merck responsible for clinical development of oncology, respiratory and immunology, infectious diseases, and vaccines in emerging markets.


Dr. Yan started his industry career with Centocor, a Johnson & Johnson company, leading both discovery and clinical development of anti-cancer biologics. He has published over 80 manuscripts and book chapters.


Dr. Yan received his medical degree from Medical College of Peking University and a Ph.D. from the University of Kansas Medical Center. He completed his post-graduate training at Beijing Cancer Hospital, Peking University, and Boston Children’s Hospital (Harvard Medical School). He is also an alumnus of the Harvard Business School enterprise executive program. Dr. Yan holds adjunct professorships at Peking University and Yonsei University, and is Managing Director of the US Chinese Anti-Cancer Association.